An Imagined Morning in 2040
This short scene is an illustration, not a prediction or a data point. Picture a weekday in 2040. A driverless car waits at the curb, and a home battery charged by midday sun runs the kettle. An AI assistant has drafted the paperwork for review, and a weekly injection keeps a relative heart risk in check.
Now notice what the picture leaves out. No flying taxi lands on the roof. No swarm of microscopic robots repairs an artery. The rent is still due, and the electric bill still stings. The rest of this article asks which parts of that morning rest on evidence, and which belong to fiction.
How to Read the Ratings
Each prediction gets one label for the window from 2035 to 2040. Likely means current deployment data and trial timelines already point there. Possible means a credible path exists, but it depends on a result nobody has yet. Unlikely means the known obstacles outweigh the known progress.
Each rating also says what would change it. Sources are named so you can check them, and any number I could not verify was left out.
Machines That Move
Self-Driving Cars
Robotaxis are real. In September 2026, TechCrunch reported that Waymo serves 15 U.S. cities and averages 500,000 paid rides each week, up from 50,000 in May 2024. Its fleet is roughly 4,000 vehicles, about 80 percent in California and Texas. Waymo reports 271.3 million rider-only miles through June 2026, with 82 percent fewer injury crashes and 95 percent fewer serious-injury-or-worse crashes than a human benchmark. These are company figures built on public crash reports.
The obstacles are rare odd situations, city-by-city permits, vehicle cost, and public trust. Regulators are investigating Waymo cars passing school buses, and tariffs raise the cost of its Chinese-built Ojai minivan. Rating: robotaxi service in many large metro areas is likely. A personal car that drives itself everywhere, including snow and rural roads, is unlikely. Safety rates holding as miles grow, or a cluster of serious failures, would move this.
Electric Air Taxis
As of early October 2026, neither Joby nor Archer holds an FAA type certificate. Joby reports it is in the fifth and final stage. Archer closed Phase 3 of four in April 2026. Dates have slipped before: in 2021 a former Archer co-CEO told CNBC the company was working toward certification by 2024. In Europe, EASA applies a special condition called SC-VTOL, and Vertical Aerospace targets UK certification in 2029.
Scale is the second limit. Joby says its Marina plant can build up to 24 aircraft per year, and its Dayton plant is designed for up to 500. Even the larger figure yields only a few thousand aircraft in a decade, and Joby has not disclosed a price. Rating: certified service on a few routes is likely, while mass commuting is unlikely. Certificates, output above several hundred aircraft yearly, and taxi-level fares would change that.
Robots and Automation
The International Federation of Robotics counted 542,076 industrial robots installed in 2024, with 4,663,773 in operation. Amazon announced in 2025 that it had deployed its one millionth robot across more than 300 facilities, mostly mobile units rather than humanoids. It also said a newer Louisiana site needs 30 percent more staff in maintenance and engineering roles.
The realistic labor effect is task shifting. Heavy lifting and sorting move to machines, while demand grows for technicians and planners. Rating: more warehouse and factory automation is likely. Humanoids at large scale in logistics are possible. Humanoids handling varied chores in ordinary homes are unlikely. Independent price and safety data from real worksites would move these.
Intelligence and Energy
AI Progress and Its Limits
The Stanford AI Index 2026 says generative AI reached 53 percent population adoption within three years. It also describes a jagged frontier: one model won gold at the International Mathematical Olympiad, yet the best model reads analog clocks correctly only 50.1 percent of the time. AI agents still fail roughly one attempt in three on structured tests.
METR measures the length of tasks that models finish at 50 percent reliability. That length doubled about every seven months from 2019 to 2025, and every 131 days since 2023. Claude Opus 4.5 scored about 320 minutes, with a wide interval of 170 to 729. Rating: AI as a routine office tool is likely. Dependable autonomous work lasting days is possible. Trust without human review in medicine or safety-critical settings is unlikely. Gains at 90 percent reliability, and fewer documented incidents (362 in 2025, up from 233), would change my view.
Cheap Energy, Lagging Bills
Generation keeps getting cheaper, yet bills have not followed. The IEA reports that from 2019 to 2024 household electricity prices rose 36 percent in the European Union and 26 percent in the United States. Net earnings for a two-earner family with two children rose 25 and 23 percent. Networks, taxes, and fees take a large share of each bill. I covered this gap in cheap solar, batteries, and rising electric bills.
Batteries help: the IEA links fewer negative-price hours in California and Texas in 2025 to growing storage. Rating: abundant cheap generation in sunny regions is likely. Household bills that fall in real terms are possible, but they depend on wires, tariffs, and rate design more than on panels. Reform of network charges would change this.
Aging Medicine: The Main Thread
What Could Exist by 2040
The strongest human evidence concerns diseases of aging, not aging itself. The SELECT trial enrolled 17,604 adults aged 45 or older with heart disease and excess weight but no diabetes. Weekly semaglutide cut the combined rate of cardiovascular death, heart attack, and stroke by 20 percent (hazard ratio 0.80) over a mean of 39.8 months. That is a real healthspan gain for a defined group. It does not show that aging slowed.
Other tools remain early. The TAME metformin trial was designed for 3,000 adults aged 65 to 79 over six years. As of September 2026, trackers found no registry record, and the sponsor still seeks donors. Reported costs run $45 to $70 million. A 2023 senolytic trial in five people with Alzheimer disease found safety but no significant cognitive change, and a 2024 trial in 60 women found no overall drop in bone resorption. Epigenetic clocks track risk across populations, yet reviews say they are not validated for individual decisions or as trial endpoints.
The Counterevidence and the Rating
Olshansky and colleagues, writing in Nature Aging in 2024, studied the eight longest-lived countries plus Hong Kong and the United States from 1990 to 2019. Gains in life expectancy slowed. Survival to age 100 is unlikely to exceed 15 percent for women and 5 percent for men. Repeating the 30.2 percent drop in old-age mortality seen in that period would add only 2.5 years of life expectancy at birth. The authors call these limits not brick walls, since a drug that slows biological aging could change them.
Rating: drugs that delay specific age-related diseases in targeted groups are possible by 2040. An approved drug for aging itself is unlikely, because TAME has not started and needs six years. Large lifespan extension is unlikely. A funded, registered trial, a clock validated against real outcomes, or a strong randomized human result would change that. For the economics, see the longevity dividend.
Nanobots and Molecular Medicine
DNA nanotechnology is a vivid research field. Reviews from 2025 list the hurdles to human use: enzymes that degrade DNA structures, poor stability in blood, immune reactions, weak targeting, and costly manufacturing. One developer in the field states it has no approved products and no open clinical trials. Nucleic-acid nanoparticle drugs have reached early trials, but they are not robots.
Rating: more precise targeted drug delivery is likely. A first DNA nanodevice therapy tested in people is possible. General-purpose medical nanobots that patrol the body are unlikely. Human safety data and clinical-scale manufacturing would change this.
Abundance, With Receipts
Harvard JCHS reports the median home price was 4.7 times median income in 2025, down from a 5.0 peak in 2022 but far above the 1990s average of 3.2. Child Care Aware puts average child care at $13,184 in 2025, which is 10 percent of median income for two-parent households and 33 percent for single parents. The College Board lists $11,950 for public in-state tuition in 2025-26. CMS projects health spending rising from 17.6 percent of GDP in 2023 to 20.3 percent in 2033.
What gets cheap is anything made of information, energy, or factory output: software, many goods, and electricity generation. What resists is land and work that needs human time, such as care and teaching. Who shares the gains is a policy choice, as I explored in who owns AI productivity gains. Rating: cheaper goods and software are likely. Falling housing, care, and health costs as a share of income are possible. True post-scarcity is unlikely.
The Rating Summary
Each rating below applies to 2035 to 2040.
- Likely: robotaxis in many metro areas; certified eVTOL on a few routes; more automation; AI as a work tool; cheap generation; cheaper goods and software; targeted drug delivery.
- Possible: humanoids at logistics scale; days-long autonomous AI work; lower bills; healthspan drugs; a first DNA nanodevice trial; cheaper housing and care.
- Unlikely: go-anywhere personal robocars; eVTOL commuting; humanoid home helpers; unsupervised high-stakes AI; an approved aging drug; large lifespan extension; general nanobots; post-scarcity.
The pattern is plain. Software and generation move fast, while physical, regulated, and human-time systems move slowly.
What Readers Can Do Now
These steps hold up whichever ratings prove right.
- Learn to use AI tools while checking their numbers and citations.
- Build skills that pair with machines, such as maintenance, analysis, and communication.
- Protect health with proven basics, and discuss any drug with a clinician.
- Plan retirement with realistic lifespans, not 100-year assumptions.
- Ask what share of an energy bill is generation versus wires.
Also test any headline: does it name a date, a regulator, a trial, or a number? If not, wait for evidence.
Conclusion: Confidence Is a Skill
The 2040 that evidence supports is useful and uneven. Rides, software, and electricity generation improve fast. Aircraft, medicine, housing, and care improve slowly, because rules, biology, land, and human time set the pace. Aging research is the key thread, and its honest rating is a hopeful maybe for healthspan and a firm unlikely for dramatic lifespan gains.
Hold forecasts loosely, and watch certificates, registered trials, safety data, and the share of household budgets. When those numbers move, the ratings should move with them.
This article is informational forecasting, not medical, financial, or legal advice.
